Is ZMP the toxic metabolite in Lesch-Nyhan disease?
The genetic deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT), located on the X chromosome, causes a severe neurological disorder in man, known as Lesch-Nyhan disease (LND). The enzyme HPRT is part of the savage pathway of purine biosynthesis and catalyzes the conversion of hypoxanthine and guanine to their respective nucleotides, IMP and GMP. HPRT deficiency is associated with a relatively selective dysfunction of brain dopamine systems. Several metabolites that accumulate in the patients (phosphoribosylpyrophosphate (PRPP), hypoxanthine, guanine, xanthine, and Z-nucleotides) have been proposed as toxic agents in LND. Some authors have pointed that Z-riboside, derived from the accumulation of ZMP, could be the toxic metabolite in LND. However, the available experimental data support a better hypothesis. I suggest that ZMP (and not Z-riboside) is the key toxic metabolite in LND. ZMP is an inhibitor of the bifunctional enzyme adenylosuccinate lyase, and a deficiency of this enzyme causes psychomotor and mental retardation in humans. Moreover, it has been reported that ZMP inhibits mitochondrial oxidative phosphorylation and induces apoptosis in certain cell types. ZMP is also an activator of the AMP-activated protein kinase (AMPK), a homeostatic regulator of energy levels in the cell. The AMPK has been implicated in the regulation of cell viability, catecholamine biosynthesis and cell structure. I propose that accumulation of ZMP will induce a pleiotropic effect in the brain by (1) a direct inhibition of mitochondrial respiration and the bifunctional enzyme adenylosuccinate lyase, and (2) a sustained activation of the AMPK which in turns would reduce cell viability, decrease dopamine synthesis, and alters cell morphology. In addition, a mechanism to explain the accumulation of ZMP in LND is presented. The knowledge of the toxic metabolite, and the way it acts, would help to design a better therapy.
López
José M
JM
Institut de Neurociencies, Departament de Bioquímica i Biología Molecular, Unitat de Bioquímica, Facultad de Medicina, Universitat Autónoma de Barcelona, 08193 Cerdanyola del Vallès. Barcelona, Spain. josemanuel.lopez@uab.es
D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives* / Q000737:chemistry / Q000633:toxicity; D045744:Cell Line, Tumor; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000378:metabolism; D007291:Inosine Monophosphate / Q000737:chemistry; D007926:Lesch-Nyhan Syndrome / Q000209:etiology* / Q000378:metabolism; D008954:Models, Biological; D008956:Models, Chemical; D008962:Models, Theoretical; D010085:Oxidative Phosphorylation; D011687:Purines / Q000737:chemistry; D012263:Ribonucleosides / Q000737:chemistry; D012265:Ribonucleotides / Q000737:chemistry / Q000633:toxicity*
D011687:Purines; D012263:Ribonucleosides; D012265:Ribonucleotides; D007291:Inosine Monophosphate; D000620:Aminoimidazole Carboxamide; C011651:acadesine; D007041:Hypoxanthine Phosphoribosyltransferase; C031143:AICA ribonucleotide